Floatz logo

Paclitaxel Poliglumex

Ovarian Serous Adenocarcinoma

GOG FoundationPhase 3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Ovarian Serous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
National Cancer Institute (NCI)
Phase 3BBB
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
Olaparib
National Cancer Institute (NCI)
Phase 2/3BB

View all 34 →

Same molecule, other indications

Paclitaxel Poliglumex is also rated in:

Primary Peritoneal CarcinomaDormant
B
Indicative ·
60 / 100
View asset →
Malignant Ovarian Mixed Epithelial TumorDormant
B
Indicative ·
56 / 100
View asset →
Ovarian Brenner TumorDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →